FOXP3-Engineered Regulatory T Cells Maintain Suppression in Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune and inflammatory central nervous system (CNS) diseases, such as Multiple Sclerosis, fail to specifically target local immune responses and often result in substantial toxicity, with existing therapies focusing on general immune suppression rather than targeted modulation.

Innovation Solution

Increasing FOXP3 expression in regulatory T cells (Tregs) by introducing exogenous FOXP3 polynucleotides to maintain their suppressive function under proinflammatory conditions, thereby stabilizing their regulatory activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If general immune suppression therapy is used, then immune responses are reduced, but specificity and targeted modulation are lost

Engineering Contradiction:

Improveimmune suppression efficacyVSAvoidtargeted modulation capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by engineering Tregs with antigen-specific receptors (TCR or CAR) that enable them to selectively recognize and suppress specific target cells expressing particular antigens. This allows the therapy to act locally and specifically on pathological immune responses while leaving other immune functions intact, resolving the contradiction between general suppression efficacy and targeted modulation capability

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If Tregs are exposed to proinflammatory conditions, then they can access sites of inflammation, but their suppressive function is lost

Engineering Contradiction:

Improveability to access inflammatory sitesVSAvoidsuppressive function

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies preliminary action by pre-engineering Tregs with enhanced FOXP3 expression and antigen-specific receptors before exposing them to proinflammatory conditions. This preliminary genetic modification ensures that the Tregs maintain their suppressive function even when subsequently exposed to challenging inflammatory environments, allowing them to both access inflammatory sites and retain their therapeutic activity

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent applies parameter changes by increasing FOXP3 expression levels in Tregs, which fundamentally alters their functional parameters. This parameter change makes the Tregs more resistant to proinflammatory conditions while maintaining their suppressive capability, enabling them to function reliably in inflammatory sites without losing their therapeutic effect

Inventive Principle:

Principle #35Parameter changes

3Reliability

If FOXP3 expression is increased in Tregs, then suppressive function is maintained under proinflammatory conditions, but cellular stability may be affected

Engineering Contradiction:

Improvesuppressive function stabilityVSAvoidcellular phenotype stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies feedback by using the endogenous FOXP3 promoter to drive exogenous FOXP3 expression, creating an autoregulatory system where FOXP3 enhances its own expression. This feedback mechanism ensures stable and sustained FOXP3 levels that maintain suppressive function without causing cellular instability or loss of regulatory phenotype, as the system self-regulates through the native promoter's control elements

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20250283039A1Method for maintaining suppressive activity of regulatory t cells

Publication Date: 2025.09.11 QUELL THERAPEUTICS LTD

AI summary

The present invention provides a method for maintaining the ability of a regulatory T cell (Treg) to suppress immune responses under proinflammatory conditions comprising introducing a polynucleotide encoding a FOXP3 polypeptide into the Treg.